Want to see GH full AI Analyst Report?
GH Stock Chart & Stats
$90.36
$0.91(2.52%)
At close: 4:00 PM EST
$90.36
$0.91(2.52%)
Day’s Range― - ―
52-Week Range$40.36 - $174.08
Previous CloseN/A
Volume639.07K
Average Volume (3M)3.11M
Market Cap
$21.22B
Enterprise Value$17.84B
Total Cash (Recent Filing)$1.10B
Total Debt (Recent Filing)$1.70B
Price to Earnings (P/E)―
Beta1.32
Next Earnings
Jul 30, 2026EPS Estimate
-0.75Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.39
Shares Outstanding132,599,930
10 Day Avg. Volume3,007,966
30 Day Avg. Volume3,108,412
Financial Highlights & Ratios
PEG Ratio4.56
Price to Book (P/B)-128.95
Price to Sales (P/S)13.04
P/FCF Ratio-54.94
Enterprise Value/Market Cap0.84
Enterprise Value/Revenue16.51
Enterprise Value/Gross Profit25.44
Enterprise Value/Ebitda-45.62
Forecast
1Y Price Target
$165.32Price Target Upside82.95% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering21
EPS Forecast (FY)-2.88
Revenue Forecast (FY)$1.31B
Bulls Say, Bears Say
Bulls Say
Revenue Growth & Raised GuidanceManagement's materially higher 2026 revenue guidance reflects durable demand across oncology, biopharma and screening channels. Sustained volume growth and multi-year guidance imply expanding adoption and predictable top-line scalability that underpins long-term operating leverage.
Screening (Shield) Traction & EconomicsRapid Shield volume ramp, national distribution (Quest), kit simplification, and falling cost per test drive structurally better unit economics. As cost-per-test targets near $200 at scale, screening can become a durable, higher-margin growth engine rather than a peripheral initiative.
Data Asset & Biopharma PartnershipsA large, proprietary data treasury and active InfinityAI/Smart Apps pipeline create a sustainable competitive advantage. Strong biopharma partnerships and growing CDx footprint translate the data moat into recurring, structural revenue streams for trials and real-world evidence.
Bears Say
Persistent Cash BurnMaterial negative operating and free cash flows persist, requiring ongoing financing or higher margins to self-fund growth. Even with improvement guidance, sustained cash burn constrains optionality and forces prioritization of near-term commercialization spend over longer-term investments.
High Leverage & Negative EquityElevated debt and negative equity weaken balance-sheet resilience, raising refinancing and covenant risk. Capital structure constraints can increase funding costs, limit strategic flexibility, and amplify execution risk if revenue or margin improvement stalls.
Reimbursement & Regulatory UncertaintyMeaningful upside depends on third-party reimbursement decisions, guideline inclusion and drug approvals. These external, timing-sensitive outcomes can delay commercial adoption and ASPs, making revenue and margin trajectories contingent on factors outside direct company control.
Guardant Health News
GH FAQ
What was Guardant Health’s price range in the past 12 months?
Guardant Health lowest stock price was $40.35 and its highest was $174.08 in the past 12 months.
What is Guardant Health’s market cap?
Guardant Health’s market cap is $21.22B.
When is Guardant Health’s upcoming earnings report date?
Guardant Health’s upcoming earnings report date is Jul 30, 2026 which is in 16 days.
How were Guardant Health’s earnings last quarter?
Guardant Health released its earnings results on May 07, 2026. The company reported -$0.85 earnings per share for the quarter, missing the consensus estimate of -$0.806 by -$0.044.
Is Guardant Health overvalued?
According to Wall Street analysts Guardant Health’s price is currently Undervalued.
Does Guardant Health pay dividends?
Guardant Health does not currently pay dividends.
What is Guardant Health’s EPS estimate?
Guardant Health’s EPS estimate is -0.75.
How many shares outstanding does Guardant Health have?
Guardant Health has 132,599,930 shares outstanding.
What happened to Guardant Health’s price movement after its last earnings report?
Guardant Health reported an EPS of -$0.85 in its last earnings report, missing expectations of -$0.806. Following the earnings report the stock price went up 3.729%.
Which hedge fund is a major shareholder of Guardant Health?
Currently, no hedge funds are holding shares in GH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Guardant Health Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$165.32 (82.95% Upside)
$165.32 (82.95% Upside)
Blogger Sentiment
Bullish
GH Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 808.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $91.7M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days <0.1%
Last 30 Days ▲ 14.5%
Last 30 Days ▲ 14.5%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
212.04%
12-Months-Change
Fundamentals
Return on Equity
184.27%
Trailing 12-Months
Asset Growth
42.48%
Trailing 12-Months
Company Description
Guardant Health
Guardant Health, Inc., established in Redwood City, California, in 2011, is a precision oncology company that delivers a range of diagnostic blood tests, comprehensive data sets, and advanced analytical solutions both within the United States and internationally. For patients with advanced-stage cancer, the company's core offerings include several liquid biopsy-based tests such as Guardant360 (available in LDT and CDx versions) and GuardantOMNI. Complementing these diagnostic tools, Guardant Health also provides GuardantINFORM, an in-silico research platform leveraging an extensive clinical-genomic liquid biopsy dataset derived from advanced cancer patients. Innovation is a key focus, with the company currently developing the LUNAR-2 test, designed for the early detection of colorectal cancer in eligible asymptomatic individuals. Another emerging solution in development is GuardantConnect, an integrated software platform intended to link biopharmaceutical and clinical clients by connecting patients whose Guardant360 tests reveal actionable alterations with potentially relevant clinical trials. Furthermore, Guardant Health offers the Guardant Reveal Test, which aids in selecting neoadjuvant and adjuvant treatments for early-stage cancer patients. Its portfolio also includes a Guardant360 product for tissue genotyping and Guardant-19 for novel coronavirus detection. The company extends its expertise to biopharmaceutical companies and medical institutions through various development services, encompassing companion diagnostic development, regulatory approval support, clinical study management (including setup, monitoring, and maintenance), testing development, and kit fulfillment.
GH Revenue Breakdown
91.19% Precision oncology testing
8.81% Development services and other
GH Stock 12 Month Forecast
Average Price Target
$165.32
▲(82.95% Upside)
Technical Analysis
Ownership Overview
3.33% Insiders
34.76% Mutual Funds
0.28% Other Institutional Investors
47.27% Public Companies and Individual Investors